Announcements Trials
Browse Landscape

Phase

Phase 3 12Phase 2 11Phase NA 3Phase EARLY_PHASE1 1Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 11Breast 3Thoracic 1Gynecologic 1

Conditions

Ovarian Neoplasms 1Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Paclitaxel 12Carboplatin 11Cisplatin 9Letrozole 6Drug Therapy 6liposomal doxorubicin 5Megestrol Acetate 4Bevacizumab 4spartalizumab 3Topotecan 3Taxes 3Medroxyprogesterone Acetate 3olaparib 2niraparib 2atezolizumab 2Methotrexate 2Magnetic Resonance Spectroscopy 2Imiquimod 2Hyperthermic Intraperitoneal Chemotherapy 2Gonadotropin-Releasing Hormone 2Gemcitabine 2Doxorubicin 21-dodecylpyridoxal 2trametinib 1sintilimab 1saracatinib 1ricin A-GnRH conjugate 1pertuzumab 1pembrolizumab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Neoadjuvant Therapy × Gynecologic × Clear all
NCT00075712 2013-08-12

Timing of Surgery and Chemotherapy in Treating Patients With Newly Diagnosed Advanced Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer

National Cancer Institute (NCI)

Phase 2/3 Completed
150 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡